Drug Information Association Conference Seeks to Formulate Innovative Thinking and Decision Making for Revitalizing R&D Productivity

Published: Oct 16, 2012

HORSHAM, PA, USA—OCTOBER 16, 2012— DIA, together with FDA, and in collaboration with Society for Clinical Trials, will host DIA/FDA: Revitalizing Productivity in Drug Development. This two-day conference in Bethesda, Maryland on October 23-24 will evaluate the status quo and the current initiatives and challenges of the pharmaceutical industry and R&D productivity in drug development with open discussions and review panels. DIA is the premier organization dedicated to knowledge exchange that fosters innovation to raise the level of health and well-being worldwide, Session topics include designing efficient clinical programs, enrichment of clinical study populations, improving clinical research’s efficiency and quality, leveraging biomarker data, and more.

Keynote Speakers:

• Robert J. Temple, MD, Deputy Center Director for Clinical Science, CDER, FDA: Keynote Address I - Revitalizing R&D: What Could We Be Doing Differently?

• by Stephen A. Arlington, PhD, Partner, Global Pharmaceutical and Life Sciences, Advisory Services Leader, PricewaterhouseCoopers LLP: Keynote Address II - An Overview of the Future for Drug Development Under the New Imperatives Delivered by Both Commercial and Regulatory Pressures

• Frank W. Rockhold, PhD, Senior Vice President, Global Clinical Safety and Pharmacovigilance, GlaxoSmithKline: Keynote Address III - How Do We Revitalize R&D in New Drug Development?

• Charles G. Beever, MBA, Vice President, Booz and Company: Keynote Address IV - Collaborative Approaches to Advancing Clinical Development

“Keynote addresses by our informative, dynamic speakers will add value and significance to this meeting while attendees learn and create solutions. This meeting’s sessions will create a forum for those to network, share thoughts on research and create solutions, visions and perspectives, and discuss upcoming initiatives to improve efficiency,” says Program Chairperson H. M. James Hung, PhD, Director, Division of Biometrics I, Office of Biostatistics, Office of Translational Sciences, CDER, FDA. “Drug development is ever-changing and we wish to offer the tools needed.”

Register here for DIA/FDA: Revitalizing Productivity in Drug Development.

About DIA

DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices and related medical products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well being worldwide. Headquarters are in Horsham, PA, USA, with offices in Basel, Switzerland; Tokyo, Japan; Mumbai, India; and Beijing, China. www.diahome.org. Follow DIA on Facebook, Twitter, LinkedIn, Flickr and YouTube. Stay updated on hot topic news at #druginfoassn on Twitter.

About FDA

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, and products that give off electronic radiation, and for regulating tobacco products.

Back to news